TBH this is total bull crap motivated by Medicare cost savings rather than what the evidence base reflects. Painful period of battling this and/or building evidence of efficacy to counter it more strongly down the track (excuse pun).
a 2RT announcement would be great about now, although the one study there isn’t a slam dunk either and needs more research/expenditure.
Could really be a great buying opportunity if the dip is overdone, equally cash burn could become a big concern if revenues stall for a long period.
Ann: Update on Proposed USA Medicare Changes, page-11
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $48.10M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.0¢ | 21.0¢ | $39.39K | 187.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38328 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 57167 | 2 |
View Market Depth
| Last trade - 15.54pm 29/08/2024 (20 minute delay) ? |
| EYE (ASX) Chart |